Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 3 , Pages 274-279, May 2010

Evaluation of renicapsular involvement in Stages I and II renal cell carcinoma from the morphological and prognostic point of view

  • Matthias May, M.D.

      Affiliations

    • Department of Urology, St. Elisabeth Hospital, Straubing, Germany
    • M.M. and S.B.-A. contributed equally to this work.
  • ,
  • Sabine Brookman-Amissah, M.D.

      Affiliations

    • Department of Urology, St. Elisabeth Hospital, Straubing, Germany
    • M.M. and S.B.-A. contributed equally to this work.
  • ,
  • Jan Roigas, M.D.

      Affiliations

    • Department of Urology, Vivantes Hospital Am Urban, Berlin, Germany
  • ,
  • Christian Peter Gilfrich, M.D.

      Affiliations

    • Department of Urology, St. Elisabeth Hospital, Straubing, Germany
  • ,
  • Sandra Pflanz, M.D.

      Affiliations

    • Department of Urology, Carl-Thiem Hospital, Cottbus, Germany
  • ,
  • Bernd Hoschke, M.D.

      Affiliations

    • Department of Urology, Carl-Thiem Hospital, Cottbus, Germany
  • ,
  • Sven Gunia, M.D.

      Affiliations

    • Institute of Pathology, HELIOS Hospital, Bad Saarow, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 33631 72312; fax: +49 33631 73010

Received 16 June 2008; received in revised form 14 July 2008; accepted 14 July 2008. published online 22 September 2008.

Abstract 

Background

Prognostic factors are essential for predicting postsurgical outcome in renal cell cancer (RCC). This study aimed to evaluate the prognostic impact of renicapsular involvement (RCI; invasion without penetration) in Stage I (pT1N0M0) and Stage II (pT2N0M0) RCC and to histomorphologically compare the structure of fibrous tumoral capsule with the pattern of RCI, the differentiation of which might by challenging in localized RCCs spreading near the renicapsule.

Materials and Methods

We retrospectively investigated a cohort of 635 study group patients (396 men and 239 women; mean age: 60.9 years; range: 18–84 years) in terms of histomorphology and clinical outcome after surgery (nephrectomy or elective nephron-sparing surgery) at Stages I and II RCC (pT1-2N0M0). In 489 patients who were still alive at the end of the study, median follow-up was 80 months (mean 86.1 months). Disease-free survival (DFS) was calculated using the Kaplan Meier method. Univariate and multivariate Cox proportional hazards regression models were fit to determine possible associations between various parameters and survival. Another 55 control group patients (38 men and 17 women) aged between 44 and 75 years (mean age 61.4 years) with pT3a RCC were analyzed for statistical comparison (mean and median follow-up of the survivors were 85.7 and 84 months).

Results

The 5-year DFS rate for patients with and without RCI was determined to be 76.9% and 86.3%, respectively (P < 0.01). Patients with histopathologically confirmed RCI appear to have the same adverse prognostic outcome as patients with RCC invading perinephric tissue (pT3aN0M0; P = 0.493). Histopathologically, fibrous tumoral capsule and RCI conventionally show a different morphology, making their separation straightforward.

Conclusions

RCI reflects adverse prognostic outcome in surgically treated Stages I and II RCC. It can be determined by the pathologist without additional expense in time and cost. Hence, clinical pathologists should render a clear statement concerning RCI when reporting on small localized RCC specimens in order to provide additional prognostic information in individual cases and to facilitate selection of appropriate patients to be included in further standardized prospective studies, which are required to confirm the prognostic impact of RCI in Stages I and II RCC.

Keywords: Localized renal cell carcinoma, Renicapsular involvement, Fibrous tumoral capsule, Histopathology, Prognostic outcome

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1078-1439(08)00166-X

doi:10.1016/j.urolonc.2008.07.008

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 3 , Pages 274-279, May 2010